Physical Activity Program for Intellectual Disability
(PACE Trial)
Trial Summary
What is the purpose of this trial?
Purpose: Conduct a wait-list randomized controlled trial (RCT) of an inclusive physical activity program called PACE for adults with intellectual disability (ID) who are not yet showing signs of Alzheimer's Disease (AD)/age-related dementias (ARD). Participants: Participants include 120 adults with ID, their caregivers, and their coaches (up to 360 individual participants, grouped as triads), recruited through the University of North Carolina at Chapel Hill and the University of Arkansas. Participants also include 16 exercise professionals. Procedures (methods): Each cohort will include 20 triads who are randomly assigned to the PACE program or the waitlist control group.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What data supports the effectiveness of the PACE Program treatment for individuals with intellectual disabilities?
Research shows that structured physical activity programs can improve physical fitness, health, and quality of life for individuals with intellectual disabilities. These programs often include education and behavior change techniques, which help increase physical activity levels and improve various health outcomes.12345
Is the Physical Activity Program for Intellectual Disability safe for participants?
How is the PACE Program treatment different from other treatments for intellectual disability?
The PACE Program is unique because it focuses on promoting physical activity specifically for individuals with intellectual disabilities, aiming to improve their physical and psychosocial well-being through long-term engagement. Unlike other treatments, it integrates community-based activities and behavior change techniques to maintain adequate levels of physical activity and improve overall fitness and daily functioning.13578
Research Team
Brianne R Tomaszewski, PhD., MPH
Principal Investigator
University of North Carolina, Chapel Hill
Eligibility Criteria
This trial is for adults with intellectual disabilities like Down Syndrome, Autism Spectrum Disorder, and several others. They should not show signs of Alzheimer's or age-related dementias. Participants will be grouped with their caregivers and coaches.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Pre-assessment
Participants and caregivers complete pre-assessments, including body composition measurements and cognitive testing
Treatment
Participants engage in a 16-week intervention including weekly group fitness classes, web-based training, and coaching meetings
Post-assessment
Post-assessment measures are conducted to evaluate the outcomes of the intervention
Follow-up
Participants are monitored for long-term outcomes, including body composition and cognitive assessments
Treatment Details
Interventions
- PACE Program (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of North Carolina, Chapel Hill
Lead Sponsor
Dr. Peggy P. McNaull
University of North Carolina, Chapel Hill
Chief Medical Officer
MD from Louisiana State University School of Medicine
Dr. Lynne Fiscus
University of North Carolina, Chapel Hill
Chief Executive Officer since 2020
MD from Georgetown University, MPH from UNC
National Institute on Aging (NIA)
Collaborator
Dr. Richard J. Hodes
National Institute on Aging (NIA)
Chief Executive Officer since 1993
MD from Harvard Medical School
Dr. Marie Bernard
National Institute on Aging (NIA)
Chief Medical Officer
MD from Harvard Medical School